Klaus Fiebig, Ph.D.
CEO & Founder, KMFBio Inc.
Dr. Fiebig is a well-respected professional in
genomics, drug discovery, biotechnology, and science funding. As
entrepreneur he has founded two companies and has extensive work
experience in biotech startups, academia, and government
not-for-profit settings. He has authored over 20 refereed papers
and book chapters and is an inventor on 3 granted US patent
Strategic design and funding of large scale research
projects. From 2006 to 2013 as CSO and VP Research
Programs at the Ontario Genomics Institute
(Toronto) Dr. Fiebig
provided strategic advice and input during the
conception of hundreds of large scale research projects; and
was responsible for a project portfolio totaling more than $800M
in federal, provincial, industry and private investments.
Large scale research management. While at
Affinium Pharmaceuticals (Toronto) as Senior Director, Structural
Biology and Computational Chemistry (2002-2006), as CEO of
MRPharm GmbH (Frankfurt) (2001-2002), and as group leader at the
Goethe University, Frankfurt (1999-2001) Dr. Fiebig was
responsible for two large collaborations with leading
Affinium-Pfizer collaboration. Dr. Fiebig was
the Affinium lead of this US $30M, 20 FTE, 3 year joint project
with Pfizer Inc. focusing on structure based drug discovery on 50
Pfizer anti-infective targets. Dr. Fiebig was also responsible
for Affinium's internal structural biology and computational
chemistry efforts on 8 internal targets.
Frankfurt University collaboration with Aventis
SA. Dr. Fiebig built up and led this US $5.5M, 8 FTE
research effort focused on NMR based drug screening. Drug
targets from all major disease groups (including oncology,
metabolic and cardiovascular diseases) of high value to Aventis
sites in Frankfurt, Vitry (near Paris), and Bridgewater (New
Jersey) were screened. This collaboration resulted in the
spin-out of MRPharm GmbH as a fee-for-service NMR based screening
provider for industry and biotech.
Technical Expertise. Dr. Fiebig's broad
technical expertise ranges from drug discovery and development to
genomics, bioinformatics, and associated technologies.
Drug discovery - small molecules. More than
5 years of biotech experience in drug screening (MRPharm GmbH)
and structure based drug design (Affinium) on a multitude of
drug targets in oncology, metabolic, cardiovascular, and
Drug discovery - biologics. While at Xencor
Inc. (Pasadena) from 1998-1999, Dr. Fiebig improved Xencor's
automated protein automated (PDA) technology and was engaged in
computational protein design of new and improved biologics for
several high value targets. While at the Ontario
Genomics Institute Dr. Fiebig was OGI's representative on the
Scientific Advisory Board of several large scale projects
aiming to discover new therapeutic antibodies for cancer.
Genomics, Protein Design, Bioinformatics, and
associated technologies. Before taking on
increasingly senior roles in industry Dr. Fiebig has had a
diverse academic career. From his undergraduate work in
Physics and a PhD degree in pharmaceutical chemistry from
UC San Francisco to postdoctoral work characterizing unfolded
proteins (Oxford University) and the protein folding mechanism
leading to membrane fusion (Yale University) he has gained a
wealth of computational and analytic skills.
Dr. Fiebig's Bio and CV are available for